drugset / Trial / NCT00914628
Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this randomized trial is to compare disease-free survival (DFS) in high risk leukemia patients who underwent haploidentical HCT followed by an add back strategy of HSV-Tk donor lymphocytes or standard haploidentical HCT
Timeline
- Start
- 2010-04-12
- Primary completion
- 2019-11-30
- Completion
- 2019-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSV-Tk | Cell therapy | 1e+07 cells/kg | — |